Can Polyethylene Glycol (PEG) 3350 be used to treat constipation in a pregnant woman?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Polyethylene Glycol (PEG) 3350 for Constipation in Pregnancy

Yes, PEG 3350 can be safely used for 4 weeks to treat constipation in this pregnant woman. 1, 2

Safety Profile in Pregnancy

  • PEG 3350 can be safely administered during pregnancy for persistent constipation, as recommended by the American College of Gastroenterology 1
  • FDA labeling advises consulting a healthcare professional before use during pregnancy, but does not contraindicate its use 2
  • Clinical studies have demonstrated PEG's safety profile in pregnant women with no significant adverse effects on maternal or fetal outcomes 3, 4

Efficacy for Constipation in Pregnancy

  • PEG has been shown to significantly increase evacuation episodes per week in pregnant women (from 1.66 ± 0.48 to 3.16 ± 1.05) 4
  • Complete resolution of constipation was achieved in 73% of pregnant women after 15 days of treatment 4
  • Recent randomized controlled trials show PEG 4000 is effective for chronic constipation during pregnancy, with 86.3% of women achieving complete spontaneous bowel movements after treatment 5

Dosing and Administration

  • Standard dosing is 17g of PEG 3350 daily mixed in 8 ounces of liquid 6
  • The American Gastroenterological Association recommends a 4-week trial period, which aligns with the proposed treatment duration 6
  • Response to PEG has been shown to be durable over 6 months in non-pregnant populations, suggesting effectiveness beyond the initial 4-week period 6

Advantages Over Other Treatments

  • PEG works as an osmotic laxative with minimal systemic absorption, making it safer than stimulant laxatives during pregnancy 7
  • Compared to lactulose, PEG has been shown to:
    • Provide faster relief of constipation symptoms 3
    • Cause fewer side effects such as bloating and flatulence 5
    • Be better tolerated by patients 8

Potential Side Effects

  • Common side effects include abdominal distension, loose stool, flatulence, and nausea, but these are generally mild to moderate 6
  • Diarrhea may occur but is typically less frequent with PEG compared to other laxatives 5, 9
  • No serious adverse events have been consistently associated with PEG use in pregnancy 3, 4

Treatment Algorithm for Constipation in Pregnancy

  1. First, recommend increasing dietary fiber (30g/day) and fluid intake 1, 7
  2. If dietary modifications are insufficient, PEG 3350 at 17g daily is appropriate 1
  3. Monitor response after 4 weeks and adjust treatment as needed 6
  4. If symptoms persist despite PEG treatment, consider additional evaluation for other causes of constipation 1

Important Considerations

  • PEG is widely available without prescription and relatively inexpensive 6
  • The American Gastroenterological Association recommends PEG with a strong recommendation and moderate certainty of evidence 6
  • PEG can be used either after a trial of fiber supplementation or in combination with fiber for enhanced efficacy 6

References

Guideline

Management of Hemorrhoids and Constipation in Pregnancy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Polyethylene glycol compared to lactulose for constipation in pregnancy: A randomized controlled trial.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2024

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Dietary Fiber Intake for Constipation Relief in Pregnancy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

OTC polyethylene glycol 3350 and pharmacists' role in managing constipation.

Journal of the American Pharmacists Association : JAPhA, 2012

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.